Biblos-e Archivo. Repositorio Institucional de la UAM
oai:repositorio.uam.es:10486/755620
Publicación
Otros (Other)
CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma
Artículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, el nombre del grupo de colaboración, si le hubiere, y los autores pertenecientes a la UAM, Clinical trial registration: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001620-29 EudraCT, ID:2014-001620-29, Background: Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma worldwide. DLBCL is an aggressive disease that can be cured with upfront standard chemoimmunotherapy schedules. However, in approximately 35-40% of the patients DLBCL relapses, and therefore, especially in this setting, the search for new prognostic and predictive biomarkers is an urgent need. Natural killer (NK) are effector cells characterized by playing an important role in antitumor immunity due to their cytotoxic capacity and a subset of circulating NK that express CD8 have a higher cytotoxic function. In this substudy of the R2-GDP-GOTEL trial, we have evaluated blood CD8+ NK cells as a predictor of treatment response and survival in relapsed/refractory (R/R) DLBCL patients.Methods: 78 patients received the R2-GDP schedule in the phase II trial. Blood samples were analyzed by flow cytometry. Statistical analyses were carried out in order to identify the prognostic potential of CD8+ NKs at baseline in R/R DLBCL patients.Results: Our results showed that the number of circulating CD8+ NKs in R/R DLBCL patients were lower than in healthy donors, and it did not change during and after treatment. Nevertheless, the level of blood CD8+ NKs at baseline was associated with complete responses in patients with R/R DLBCL. In addition, we also demonstrated that CD8+ NKs levels have potential prognostic value in terms of overall survival in R/R DLBCL patients.Conclusion: CD8+ NKs represent a new biomarker with prediction and prognosis potential to be considered in the clinical management of patients with R/R DLBCL, The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was funded by the Spanish Lymphoma Oncology Group (GOTEL) with the financial support of Celgene (Investigator Initiated Trials Program); no grant numbers applicable. LH-P is supported by the Consejerı́a de Salud y Familias, Junta de Andalucı́a (RH-0047-2021) and Miguel Servet Researcher Fellow from the
Instituto de Salud Carlos III. DG-D is supported by the VII Plan Propio de Investigacion y Transferencia of Universidad de Sevilla [Contrato de Acceso (II.4)/VII PPIT-US]. CJ-C is supported by the Margarita Salas fellowship, granted by the University of Seville (Seville, Spain)
DOI: https://hdl.handle.net/10486/755620, https://dx.doi.org/10.3389/fimmu.2024.1293931, 38469299
Biblos-e Archivo. Repositorio Institucional de la UAM
oai:repositorio.uam.es:10486/755620
HANDLE: https://hdl.handle.net/10486/755620, https://dx.doi.org/10.3389/fimmu.2024.1293931, 38469299
Biblos-e Archivo. Repositorio Institucional de la UAM
oai:repositorio.uam.es:10486/755620
PMID: https://hdl.handle.net/10486/755620, https://dx.doi.org/10.3389/fimmu.2024.1293931, 38469299
Biblos-e Archivo. Repositorio Institucional de la UAM
oai:repositorio.uam.es:10486/755620
Ver en: https://hdl.handle.net/10486/755620, https://dx.doi.org/10.3389/fimmu.2024.1293931, 38469299
Biblos-e Archivo. Repositorio Institucional de la UAM
oai:repositorio.uam.es:10486/755620